Nucleoside analogs: ready to enter the era of precision medicine?

References

• Chang C, Swaan PW, Ngo LY, et al. Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. Mol Pharmacol. 2004;65(3):558–570.
   PubMed Web of Science ®Google Scholar
• Marce S, Molina-Arcas M, Villamor N, et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica. 2006;91(7):895–902.
   PubMed Web of Science ®Google Scholar
• Kawada N, Uehara H, Katayama K, et al. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine. J Hepato-Biliary-Pancreat Sci. 2012;19(6):717–722.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Murakami Y, Uemura K, et al. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann Surg. 2012;256(2):288–296.
   PubMed Web of Science ®Google Scholar
• Matsumura N, Nakamura Y, Kohjimoto Y, et al. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int. 2011;108(2 Pt 2):E110–6.
   Google Scholar
• Oguri T, Achiwa H, Muramatsu H, et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett. 2007;256(1):112–119.
   PubMed Web of Science ®Google Scholar
• Ormanns S, Heinemann V, Raponi M, et al. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. Eur J Cancer. 2014;50(11):1891–1899.
   PubMed Web of Science ®Google Scholar
• Santini D, Schiavon G, Vincenzi B, et al. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets. 2011;11(1):123–129.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Murakami Y, Uemura K, et al. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. Br J Cancer. 2014;111(7):1275–1284.
   PubMed Web of Science ®Google Scholar
• Nordh S. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. World J Gastroenterol. 2014;20(26):8482.
   PubMed Web of Science ®Google Scholar
• Jordheim LP, Dumontet C. Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? Biomark Med. 2013;7(4):663–671.
   PubMed Web of Science ®Google Scholar
• Liu Z-Q, Han Y-C, Zhang X, et al. Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. Plos ONE [Internet]. 2014;9(1). [cited 2016 Feb 24]. Available from : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903621/
   Web of Science ®Google Scholar
• Marechal R, Mackey JR, Lai R, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 2009;15(8):2913– 2919.
   PubMed Web of Science ®Google Scholar
• Lane J, Martin TA, McGuigan C, et al. The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. J Exp Ther Oncol. 2010;8(3):203–210.
   PubMedGoogle Scholar
• Lee S-Y, Im S-A, Park YH, et al. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. Eur J Cancer Oxf Engl 1990. 2014;50(4):698–705.
   PubMed Web of Science ®Google Scholar
• Hubeek I, Stam RW, Peters GJ, et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer. 2005;93(12):1388–1394.
   PubMed Web of Science ®Google Scholar
• Stam RW, Den Boer ML, Meijerink JPP, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood. 2003;101(4):1270–1276.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Thomas X, Calvo F, et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol. 2002;117(4):860–868.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Thomas X, Calvo F, et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res. 2002;26(7):621–629.
   PubMed Web of Science ®Google Scholar
• Wan H, Zhu J, Chen F, et al. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res CR [Internet]. 2014;33(1). [cited 2016 Feb 23]. Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234887/
   Web of Science ®Google Scholar
• Miyamoto Y, Lenz H-J, Baba H. A novel antimetabolite: TAS-102 for metastatic colorectal cancer. Expert Rev Clin Pharmacol. 2016;9(3):355–365.
   PubMed Web of Science ®Google Scholar
• García-González X, Cortejoso L, García MI, et al. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget. 2015;6(8):6422–6430.
   PubMed Web of Science ®Google Scholar
• Homminga I, Zwaan CM, Manz CY, et al. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. Blood. 2011;118(8):2184–2190.
   PubMed Web of Science ®Google Scholar
• Lamba JK, Crews K, Pounds S, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007;323(3):935–945.
   PubMed Web of Science ®Google Scholar
• Baker JAR, Wickremsinhe ER, Li CH, et al. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug Metab Dispos. 2013;41(3):541–545.
   PubMed Web of Science ®Google Scholar
• Klanova M, Lorkova L, Vit O, et al. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogues gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Mol Cancer. 2014;13:159.
   PubMed Web of Science ®Google Scholar
• Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 2002;5(1):19–33.
   PubMed Web of Science ®Google Scholar
• Bergman AM, Pinedo HM, Jongsma APM, et al. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol. 1999;57(4):397–406.
   PubMed Web of Science ®Google Scholar
• Banklau C, Jindadamrongwech S, Sawangpanich R, et al. Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia. Hematol Oncol Stem Cell Ther. 2010;3(3):103–108.
   PubMedGoogle Scholar
• Song JH, Kim SH, Kweon SH, et al. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Int J Oncol. 2009;34(4):1165– 1171.
   PubMed Web of Science ®Google Scholar
• Gabor KM, Schermann G, Lautner-Csorba O, et al. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia: SNPs in cytarabine toxicity in pediatric ALL. Pediatr Blood Cancer. 2015;62(4):622–628.
   PubMed Web of Science ®Google Scholar
• Kakihar T, Fukuda T, Tanaka A, et al. Expression of Deoxycytidine Kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. Leuk Lymphoma. 1998;31(3–4):405–409.
   PubMed Web of Science ®Google Scholar
• Van der Wilt CL, Kroep JR, Loves WJP, et al. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. Eur J Cancer. 2003;39(5):691–697.
   PubMed Web of Science ®Google Scholar
• McAllister F, Pineda DM, Jimbo M, et al. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer. Cancer Biol Ther. 2014;15(6):688–698.
   PubMed Web of Science ®Google Scholar
• Roumier C, Cheok MH. Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics. 2009;10(11):1839–1851.
   PubMed Web of Science ®Google Scholar
• Kocabas NA, Aksoy P, Pelleymounter LL, et al. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos Biol Fate Chem. 2008;36(9):1951–1959.
   PubMed Web of Science ®Google Scholar
• Woo HI, Kim KK, Choi H, et al. Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. Pharmacogenomics. 2012;13(9):1023–1035.
   PubMed Web of Science ®Google Scholar
• Cividini F, Filoni DN, Pesi R, et al. IMP-GMP specific cytosolic 5ʹ-nucleotidase regulates nucleotide pool and prodrug metabolism. Biochim Biophys Acta. 2015;1850(7):1354–1361.
   PubMed Web of Science ®Google Scholar
• Mitra AK, Crews KR, Pounds S, et al. Genetic variants in cytosolic 5ʹ-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011;339(1):9–23.
   PubMed Web of Science ®Google Scholar
• Falk IJ, Fyrberg A, Paul E, et al. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5ʹ-nucleotidase. Am J Hematol. 2013;88(12):1001–1006.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Fina F, Bezulier K, et al. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, xeloda, is mediated via Fas 1 Mol. Cancer Ther. 2002;1(11):923– 927.
   Google Scholar
• Terranova-Barberio M, Roca MS, Zotti AI, et al. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget. 2015;7(7):7715–7731
   Web of Science ®Google Scholar
• Ciccolini J, Peillard L, Evrard A, et al. Enhanced antitumor activity of 5-fluorouracil in combination with 2ʹ-deoxyinosine in human colorectal cell lines and human colon tumor xenografts. Clin Cancer Res Off J Am Assoc Cancer Res. 2000;6(4):1529–1535.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Evrard A, Cuq P. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anti-Cancer Agents. 2004;4(2):71–81.
   PubMedGoogle Scholar
• Elamin YY, Rafee S, Osman NO, et al. Thymidine phosphorylase in cancer; enemy or friend?. Cancer Microenviron Off J Int Cancer Microenviron Soc. 2015;9:33–43.
   Google Scholar
• Lu M, Gao J, Wang X, et al. Expressions of thymidylate synthase, thymidine phosphorylase, Class III β-tubulin, and excision repair cross-complementing group 1predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin. Chin J Cancer Res. 2011;23(4):288–294.
   PubMed Web of Science ®Google Scholar
• Milano G, Etienne-Grimaldi M-C, Mari M, et al. Candidate mechanisms for capecitabine-related hand–foot syndrome. Br J Clin Pharmacol. 2008;66(1):88–95.
   PubMed Web of Science ®Google Scholar
• Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(suppl 5):v7–12.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Mercier C, Dahan L, et al. Integrating pharmacogenetics into gemcitabine dosing–time for a change? Nat Rev Clin Oncol. 2011;8(7):439–444.
   PubMed Web of Science ®Google Scholar
• Sebastiani V, Ricci F, Rubio-Viqueira B, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(8):2492–2497.
   PubMed Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457–1461.
   PubMed Web of Science ®Google Scholar
• Silvestris N, Gnoni A, Brunetti AE, et al. Target therapies in pancreatic carcinoma. Curr Med Chem. 2014;21(8):948–965.
   PubMed Web of Science ®Google Scholar
• Eadon MT, Wheeler HE, Stark AL, et al. Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet. 2013;22(19):4007–4020.
   PubMed Web of Science ®Google Scholar
• Villafranca E, Okruzhnov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(6):1779–1786.
   PubMed Web of Science ®Google Scholar
• Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer. 2001;85(6):827–831.
   PubMed Web of Science ®Google Scholar
• Marsh S, McKay JA, Cassidy J, et al. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol. 2001;19(2):383–386.
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema ADR, Boot H, et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol. 2015;75(4):763– 772.
   PubMed Web of Science ®Google Scholar
• Gao J, He Q, Hua D, et al. Polymorphism of TS 3ʹ-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2013;15(8):619–625.
   Web of Science ®Google Scholar
• Loganayagam A, Arenas Hernandez M, Corrigan A, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013;108(12):2505–2515.
   PubMed Web of Science ®Google Scholar
• Sharma R, Hoskins JM, Rivory LP, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(3):817–825.
   PubMed Web of Science ®Google Scholar
• Weekes CD, Nallapareddy S, Rudek MA, et al. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs. 2011;29(5):1057–1065.
   PubMed Web of Science ®Google Scholar
• Rosmarin D, Palles C, Pagnamenta A, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015;64(1):111–120.
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi M-C, Milano G, Maindrault-Gœbel F, et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol. 2010;69(1):58–66.
   PubMed Web of Science ®Google Scholar
• Cecchin E, Agostini M, Pucciarelli S, et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J. 2011;11(3):214–226.
   PubMed Web of Science ®Google Scholar
• Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(13):2118–2123.
   PubMed Web of Science ®Google Scholar
• Van Huis-Tanja LH, Gelderblom H, Punt CJA, et al. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. Pharmacogenet Genomics. 2013;23(4):208–218.
   PubMed Web of Science ®Google Scholar
• Zhao J, Li W, Zhu D, et al. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med Oncol. 2014;31(1):802.
   PubMed Web of Science ®Google Scholar
• Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32(10):1031–1039.
   PubMed Web of Science ®Google Scholar
• Navaratnam N, Sarwar R. An overview of cytidine deaminases. Int J Hematol. 2006;83(3):195–200.
   PubMed Web of Science ®Google Scholar
• Lilly E Monography of Gemzar. 2006; Available from: www.gemzar.com
   Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–2413.
   PubMed Web of Science ®Google Scholar
• Abraham A, Varatharajan S, Abbas S, et al. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics. 2012;13(3):269–282.
   PubMed Web of Science ®Google Scholar
• Serdjebi C, Milano G, Ciccolini J. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. Expert Opin Drug Metab Toxicol. 2015;11(5):665–672.
   Google Scholar
• Yue L, Saikawa Y, Ota K, et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics. 2003;13(1):29–38.
   PubMedGoogle Scholar
• Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol. 1996;24(11):1340–1346.
   PubMed Web of Science ®Google Scholar
• Kirch HC, Schroder J, Hoppe H, et al. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol. 1998;26(5):421–425.
   PubMed Web of Science ®Google Scholar
• Chabner BA, Drake JC, Johns DG. Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Biochem Pharmacol. 1973;22(21):2763–2765.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Dahan L, André N, et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(1):160– 165.
   PubMed Web of Science ®Google Scholar
• Okamura T, Kigasawa K, Takeuchi T, et al. Cytidine deaminase activity in abnormal pregnancy. Int J Gynaecol Obstet. 1993;41(1):53–60.
   PubMed Web of Science ®Google Scholar
• Mercier C, Raynal C, Dahan L, et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics. 2007;17(10):841– 844.
   PubMed Web of Science ®Google Scholar
• Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797–1803.
   PubMed Web of Science ®Google Scholar
• Tibaldi C, Giovannetti E, Tiseo M, et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol. 2012;23(3):670–677.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Javle M, Tanaka M, et al. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res. 2010;16(1):320–329.
   PubMed Web of Science ®Google Scholar
• Carpi FM, Vincenzetti S, Ubaldi J, et al. CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population. Pharmacogenomics. 2013;14(7):769–781.
   PubMed Web of Science ®Google Scholar
• Ludovini V, Floriani I, Pistola L, et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol. 2011;6(12):2018–2026.
   PubMed Web of Science ®Google Scholar
• Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. Aaps J. 2012;14(1):119–132.
   PubMed Web of Science ®Google Scholar
• Serdjebi C, Gagnière J, Desramé J, et al. FFCD-1004 clinical trial: impact of cytidine deaminase activity on clinical outcome in gemcitabine-monotherapy treated patients. PloS One. 2015;10(8):e0135907.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Mercier C, Serdjebi C, et al. Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome. Pharmacogenet Genomics. 2015;25(6):317–321.
   PubMed Web of Science ®Google Scholar
• Mercier C, Dupuis C, Blesius A, et al. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother Pharmacol. 2009;63(6):1177–1180.
   PubMed Web of Science ®Google Scholar
• Dahan L, Ciccolini J, Evrard A, et al. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications. J Clin Oncol. 2012;30(4):e41–e44.
   PubMed Web of Science ®Google Scholar
• Serdjebi C, Seitz JF, Ciccolini J, et al. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics. 2013;14(9):1047–1051.
   PubMed Web of Science ®Google Scholar
• Micozzi D, Carpi FM, Pucciarelli S, et al. Human cytidine deaminase: a biochemical characterization of its naturally occurring variants. Int J Biol Macromol. 2014;63:64–74.
   PubMed Web of Science ®Google Scholar
• Gilbert JA, Salavaggione OE, Ji Y, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res. 2006;12(6):1794–1803.
   PubMed Web of Science ®Google Scholar
• Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol. 2007;25(1):32–42.
   PubMed Web of Science ®Google Scholar
• Sugiyama E, Kaniwa N, Kim SR, et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet. 2010;49(8):549–558.
   PubMed Web of Science ®Google Scholar
• Caronia D, Martin M, Sastre J, et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res. 2011;17(7):2006–2013.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Mercier C, Serdjebi C, et al. Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale. Pharmacogenomics. 2015;16(17):1907–1912.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Evrard A, M’Batchi L, et al. CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics. 2012;13(4):393–397.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Honeywell RJ, Maulandi M, et al. Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. Nucleosides Nucleotides Nucleic Acids. 2014;33(4–6):403–412.
   PubMed Web of Science ®Google Scholar
• Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939–950.
   PubMed Web of Science ®Google Scholar
• Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol Off J Am Soc Clin Oncol. 1994;12(11):2248–2253.
   PubMed Web of Science ®Google Scholar
• Tuchman M, Roemeling RV, Hrushesky WA, et al. Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells. Enzyme. 1989;42(1):15–24.
   PubMedGoogle Scholar
• Ciccolini J, Mercier C, Dahan L, et al. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol. 2006;58(2):272–275.
   PubMed Web of Science ®Google Scholar
• Largillier R, Etienne-Grimaldi MC, Formento JL, et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res. 2006;12(18):5496–5502.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, van Hasselt JGC, Huitema ADR, et al. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. Eur J Cancer Oxf Engl 1990. 2016;54:120–130.
   PubMed Web of Science ®Google Scholar
• Mercier C, Ciccolini J. Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci. 2007;28(12):597–598.
   PubMed Web of Science ®Google Scholar
• Gross E, Busse B, Riemenschneider M, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PloS One. 2008;3(12):e4003.
   PubMed Web of Science ®Google Scholar
• Deenen MJ, Tol J, Burylo AM, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(10):3455–3468.
   PubMed Web of Science ®Google Scholar
• Froehlich TK, Amstutz U, Aebi S, et al. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer. 2015;136(3):730–739.
   PubMed Web of Science ®Google Scholar
• Offer SM, Fossum CC, Wegner NJ, et al. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74(9):2545–2554.
   PubMed Web of Science ®Google Scholar
• Ciccolini J. Editorial: targeted therapy, targeted dosing and targeted delivery in oncology: where do we stand? Curr Top Med Chem. 2012;12(15):1638.
   PubMed Web of Science ®Google Scholar
• Beumer JH. Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther. 2013;93(3):228–230.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Yee SW, Ratain MJ, et al. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med. 2012;4(153):153ps18.
   PubMed Web of Science ®Google Scholar
• Andre F, Ciccolini J, Spano JP, et al. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics. 2013;14(8):931–939.
   PubMed Web of Science ®Google Scholar
• Monjanel-Mouterde S, Lejeune C, Ciccolini J, et al. Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer. J Clin Pharm Ther. 2002;27(3):189–195.
   PubMed Web of Science ®Google Scholar
• Di Paolo A, Ibrahim T, Danesi R, et al. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Ther Drug Monit. 2002;24(5):588–593.
   PubMed Web of Science ®Google Scholar
• Dupuis C, Mercier C, Yang C, et al. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs. 2008;19(3):267–273.
   PubMed Web of Science ®Google Scholar
• Mercier C, Ciccolini J, Pourroy B, et al. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit. 2006;28(2):212–218.
   PubMed Web of Science ®Google Scholar
• Salas S, Mercier C, Ciccolini J, et al. Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit. 2006;28(4):532–539.
   PubMed Web of Science ®Google Scholar
• Paci A, Vassal G, Moshous D, et al. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther Drug Monit. 2012;34(2):198–208.
   PubMed Web of Science ®Google Scholar
• Van Warmerdam LJ, Rodenhuis S, Ten Bokkel Huinink WW, et al. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol. 1996;37(3):266–270.
   PubMed Web of Science ®Google Scholar
• Schmitt A, Gladieff L, Laffont CM, et al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol. 2010;28(30):4568–4574.
   PubMed Web of Science ®Google Scholar
• Launay M, Dahan L, Duval M, et al. Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. Br J Clin Pharmacol. 2016;81(1):124–130.
   PubMed Web of Science ®Google Scholar
• Deenen MJ, Meulendijks D, Cats A, et al. Upfront genotyping of DPYD*2A to Individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(3):227–234.
   PubMed Web of Science ®Google Scholar
• Soo RA, Lim HL, Wang LZ, et al. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a cancer therapeutics research group study. Cancer Chemother Pharmacol. 2003;52(2):153–158.
   PubMed Web of Science ®Google Scholar
• Fogli S, Danesi R, De Braud F, et al. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2001;12(11):1553–1559.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Schleyer E, Unterhalt M, et al. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. Ther Drug Monit. 1996;18(4):341–349.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Estey E, Keating MJ, et al. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 1989;7(5):622–628.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Estey EH, Plunkett W, et al. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med. 1986;81(3):387–394.
   PubMed Web of Science ®Google Scholar
• Shnider BI, Baig M, Colsky J. A phase I study of 5-azacytidine (NSC-102816). J Clin Pharmacol. 1976;16(4):205–212.
   PubMed Web of Science ®Google Scholar
• Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(19):6296–6301.
   PubMed Web of Science ®Google Scholar
• Uchida T, Ogawa Y, Kobayashi Y, et al. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci. 2011;102(9):1680–1686.
   PubMed Web of Science ®Google Scholar
• Cogle CR, Scott BL, Boyd T, et al. Oral azacitidine (CC-486) for the treatment of myelodysplastic syndromes and acute myeloid leukemia. The Oncologist. 2015;20(12):1404–1412.
   PubMed Web of Science ®Google Scholar
• Van Groeningen CJ, Leyva A, O’Brien AM, et al. Phase I and pharmacokinetic study of 5-aza-2ʹ-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986;46(9):4831–4836.
   PubMed Web of Science ®Google Scholar
• Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(29):4603–4609.
   PubMed Web of Science ®Google Scholar
• Long-Boyle JR, Green KG, Brunstein CG, et al. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant. 2011;46(1):20–26.
   PubMed Web of Science ®Google Scholar
• Bonate PL, Cunningham CC, Gaynon P, et al. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol. 2011;67(4):875–890.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005;106(13):4253–4260.
   PubMed Web of Science ®Google Scholar
• Pronk LC, Vasey P, Sparreboom A, et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer. 2000;83(1):22–29.
   PubMed Web of Science ®Google Scholar
• Villalona-Calero MA, Blum JL, Jones SE, et al. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2001;12(5):605–614.
   PubMed Web of Science ®Google Scholar
• Gieschke R, Burger H-U, Reigner B, et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol. 2003;55(3):252–263.
   PubMed Web of Science ®Google Scholar
• Derissen EJB, Jacobs BAW, Huitema ADR, et al. Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. Br J Clin Pharmacol. 2016;81(5):949–957.
   PubMed Web of Science ®Google Scholar
• Doi T, Ohtsu A, Yoshino T, et al. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer. 2012;107(3):429–434.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Varadhachary G, Kopetz S, et al. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008;26(5):445–454.
   PubMed Web of Science ®Google Scholar
• Shahrokni A, Rajebi MR, Saif MW. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer. 2009;8(4):231–234.
   PubMed Web of Science ®Google Scholar
• Wheeler HE, Maitland ML, Dolan ME, et al. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013;14(1):23–34.
   PubMed Web of Science ®Google Scholar
• Uchida K, Danenberg PV, Danenberg KD, et al. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer. 2008;8:386.
   PubMed Web of Science ®Google Scholar
• Bins S, Ratain MJ, Mathijssen RHJ. Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin Pharmacol Ther. 2014;95(4):361–364.
   PubMed Web of Science ®Google Scholar
• Widmer N, Bardin C, Chatelut E, et al. Review of therapeutic drug monitoring of anticancer drugs part two–targeted therapies. Eur J Cancer. 2014;50(12):2020–2036.
   PubMed Web of Science ®Google Scholar
• Paci A, Veal G, Bardin C, et al. Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics. Eur J Cancer. 2014;50(12):2010–2009.
   PubMed Web of Science ®Google Scholar
• Fuchs A, Csajka C, Thoma Y, et al. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52(1):9–22.
   PubMed Web of Science ®Google Scholar
• Iasonos A, O’Quigley J. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(23):2505–2511.
   PubMed Web of Science ®Google Scholar
• Bruno R, Mercier F, Claret L. Model-based drug development in oncology: what’s next? Clin Pharmacol Ther. 2013;93(4):303–305.
   PubMed Web of Science ®Google Scholar
• Cook N, Hansen AR, Siu LL, et al. Early phase clinical trials to identify optimal dosing and safety. Mol Oncol. 2015;9(5):997–1007.
   PubMed Web of Science ®Google Scholar
• Harrington JA, Wheeler GM, Sweeting MJ, et al. Adaptive designs for dual-agent phase I dose-escalation studies. Nat Rev Clin Oncol. 2013;10(5):277–288.
   PubMed Web of Science ®Google Scholar
• Chefrour M, Fischel J-L, Formento P, et al. Erlotinib in combination with capecitabine (5ʹdFUR) in resistant pancreatic cancer cell lines. J Chemother Florence Italy. 2010;22(2):129–133.
   PubMed Web of Science ®Google Scholar
• Barbolosi D, Ciccolini J, Lacarelle B, et al. Computational oncology - mathematical modelling of drug regimens for precision medicine. Nat Rev Clin Oncol. 2016;13(4):242–254.
   PubMed Web of Science ®Google Scholar